Poorer survival and disease progression were associated with higher CRP levels.
Multiple studies have been performed to look for serological markers of melanoma prognosis and progression. Immune and inflammatory mechanisms have a role in melanoma prognosis. C-reactive protein (CRP) is synthesized in response to proinflammatory cytokines, and elevated levels are a known cardiovascular risk marker. It has been associated with poor prognosis in breast, lung, and other cancers, and results of a previous study suggest that it could be prognostic in early-stage melanoma.
These investigators examined plasma samples from 1144 patients with melanoma for CRP determination. Their primary aim was to discover whether increased levels of CRP in plasma were associated with melanoma disease stage, recurrence, or survival. Elevated CRP …
Reviewing Author
DisclosuresConsultant / advisory board Lubax; WorldCare Clinical
EquityLubax
Grant / Research support NIH; Department of Defense; American Skin Association; Piramal
Editorial boardsBritish Journal of Dermatology; Journal of the American Academy of Dermatology; Journal of Investigative Dermatology
Leadership positions in professional societies American Academy of Dermatology (Chair, Skin Cancer and Melanoma Committee); American Board of Dermatology (Director)
DisclosuresConsultant / advisory board Lubax; WorldCare Clinical
EquityLubax
Grant / Research support NIH; Department of Defense; American Skin Association; Piramal
Editorial boardsBritish Journal of Dermatology; Journal of the American Academy of Dermatology; Journal of Investigative Dermatology
Leadership positions in professional societies American Academy of Dermatology (Chair, Skin Cancer and Melanoma Committee); American Board of Dermatology (Director)